Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders

Biological Psychiatry

Volumn 62, Issue 3, 2007, Pages 226-234

  Pandina, Gahan J ^a   Bilder, Robert ^b,c   Harvey, Philip D ^d   Keefe, Richard S E ^e   Aman, Michael G ^f   Gharabawi, Georges ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Attention; cognition; DBDs; memory; pediatric; risperidone

Indexed keywords

PLACEBO; RISPERIDONE;

ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; DISRUPTIVE BEHAVIOR; DRUG WITHDRAWAL; HUMAN; LEARNING; MEMORY; OPEN STUDY; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SOMNOLENCE; TASK PERFORMANCE; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD, PRESCHOOL; COGNITION; CONDUCT DISORDER; DOUBLE-BLIND METHOD; HUMANS; INTELLIGENCE; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; VERBAL LEARNING;

EID: 34447285716     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.09.036     Document Type: Article

References (22)

1. Aman M.G., De Smedt G., Derivan A., Lyons B., Findling R.L., and Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159 (2002) 1337-1346
2. Aman M.G., Singh N.N., Stewart A.W., and Field C.J. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89 (1985) 485-491
3. Aman M.G., Tasse M.J., Rojahn J., and Hammer D. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil 17 (1996) 41-57
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (2000), American Psychiatric Association, Washington, DC
5. Baird J., Stevenson J.C., and Williams D.C. The evolution of ADHD: a disorder of communication?. Q Rev Biol 75 (2000) 17-35
6. Burke J.D., Loeber R., and Birmaher B. Oppositional defiant disorder and conduct disorder: a review of the past 10 years, part II. J Am Acad Child Adolesc Psychiatry 41 (2002) 1275-1293
7. Croonenberghs J., Fegert J.M., Findling R.L., De Smedt G., Van Dongen S., and Risperidone Disruptive Behavior Study Group. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a one-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44 (2005) 64-72
8. Delis D.C., Kamer J.H., Kaplan E., and Ober B.A. CVLT-C: California Verbal Learning Test-Children's Version (1994), The Psychological Corporation, San Antonio, TX
9. Dunn L.M., and Dunn L.M. Peabody Picture Vocabulary Test-Third Edition (1997), AGS Publishing, Circle Pines, MN
10. Findling R.L., Aman M., Eerdekens M., Derivan A., Lyons B., and the Risperidone Disruptive Behavior Study Group. Long-term open-label study of risperidone in children with severe disruptive behaviors and subaverage intelligence. Am J Psychiatry 161 (2004) 677-684
11. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr Bull 26 (2000) 119-136
12. Harvey P.D., Green M.F., McGurk S.R., and Meltzer H.Y. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 169 (2003) 404-411
13. Harvey P.D., and Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158 (2001) 176-184
14. Harvey P.D., Napolitano J.A., Mao L., and Gharabawi G. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry 18 (2003) 820-829
15. Harvey P.D., Rabinowitz J., Eerdekens M., and Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 162 (2005) 1888-1895
16. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., et al., Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347 (2002) 314-321
17. Rutschmann J., Cornblatt B., and Erlenmeyer-Kimling L. Sustained attention in children at risk for schizophrenia. Report on a continuous performance test. Arch Gen Psychiatry 34 (1977) 571-575
18. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 (2004) e634-e641
19. Snodgrass J.G., and Corwin J. Pragmatics of measuring recognition memory: Applications to dementia and amnesia. J Exp Psychol 117 (1988) 34-50
20. Snyder R., Turgay A., Aman M., Binder C., Fisman S., Carroll A., and the Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41 (2002) 1026-1036
21. Sparrow S.S., Balla D.A., and Cicchetti D.V. Vineland Adaptive Behavior Scales (1984), AGS Publishing, Circle Pines, MN
22. Turgay A., Binder C., Snyder R., and Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110 (2002) e34